Novamed-Medley deal under complex scrutiny in Brazil
Brazil's competition authority has declared its review of Novamed's proposed acquisition of Medley from Sanofi to be complex, saying the transaction raises competition concerns in two pharmaceutical markets where the combined...To view the full article, register now.
Already a subscriber? Click here to view full article